PDCD1 and neoplasm: By targeting effector phase lymphocytes, PD-1 inhibition exhibits a more restricted pattern of immune upregulation compared with CTLA-4 suppression, which grants fewer immune-mediated side effects and a shorter time lag before complete tumor response than with ipilimumab, as TILs are already present in metastases.